← Eichor
Study identifier: NCT06076200 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations

Condition: Early-Onset Neonatal Sepsis  ·  Sponsor: Shandong University

PhaseN/A
Planned participants50
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin/tazobactam after intravenous administration in pregnant women during pregnancy and delivery, and to evaluate pharmacodynamic effectiveness and safety of piperacillin/tazobactam in pregnant women whose baby are at high risk of developing early-onset sepsis after birth.

This description comes directly from the study's public registry record.

Talk to the study team

Wei Zhao, Ph.D  ·  86053188383308  ·  zhao4wei2@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shandong Provincial HospitalJinan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06076200